Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  CRUK funded Clinical Research Fellowship: Characterising determinants of sensitivity to kinase inhibitors in acute myeloid leukaemia


   Barts and The London School of Medicine and Dentistry

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr P R Cutillas, Dr J Fitzgibbon  No more applications being accepted  Competition Funded PhD Project (European/UK Students Only)

About the Project

Our CRUK funded Clinical Research Fellowship provides up to 3 years’ support for clinically qualified professionals to undertake research training within Barts Cancer Institute.

This training programme, part of a multimillion pound award from CRUK, aims to develop a cohort of medically qualified scientists equipped both intellectually and technically to conduct the highest quality research on cancer.

The scheme is designed to accommodate the dual clinical-research training career path by allowing fellows to spend up to 20% of theor time on NHS sessions

Fellows will be appointed as a Clinical Research Fellow with the Institute and will be required to register for a PhD, based on research undertaken during the fellowship.


Project Outline:

Acute myeloid leukaemia (AML) is the most common form of acute leukaemia. Seventy per cent of patients die from their disease, mostly within the first 12 months of diagnosis. Intense research on this field has shown that many of the genetic mutations linked to AML are in genes in biochemical pathways that regulate cell communication. When overactive, these so called signalling pathways trigger many of characteristic features of cancer.

Somewhat disappointingly, drugs that target these genetic alterations have so far not been particularly effective in AML. This project will test the hypothesis that resistance to our existing treatments reflect not just the activity of single biochemical pathways but the cumulative activity of the AMLs cell signalling, which may be different in different patients.

The successful candidate will be trained in advanced proteomics methodologies (some of which have been developed by the host laboratory) and these will be used to investigate determinants of sensitivity to compounds of current interest in AML. We expect that this work will characterise the relevance of new drug targets in leukaemia and will also identify associated markers of sensitivity can then be tested in clinical trials.


For more information, including details on how to apply please see our website:
http://www.bci.qmul.ac.uk/study-with-us/postgraduate-research/cruk-funded-clinical-research-fellowships-2017-18


Funding Notes

The fellowship will cover tuition fees for PhD registration up to the Home/EU rate.

If you are considered an overseas applicant for fee purposes, you will be responsible for paying the difference between the Home/EU and overseas rate.

You will also receive a salary commensurate with your current experience.

How good is research at Queen Mary University of London in Clinical Medicine?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities